Analyst Research and Recommendations: Ascendis Pharma A/S (ASND), Regional Management Corp. (RM)

Ascendis Pharma A/S (NASDAQ:ASND) tinted gains of +0.49% (+0.32 points) to US$64.99. The volume of 0.09 Million shares climbed down over an trading activity of 116.3 Million shares. EPS ratio determined by looking at last 12 month figures is -4.08. Over the same time span, the stock marked US$76.99 as its best level and the lowest price reached was US$36.07. The corporation has a market cap of US$2.68 Billion.

Ascendis Pharma A/S (NASDAQ:ASND)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as -37.1 percent. The return on equity ratio or ROE stands at -49.5 percent while most common profitability ratio return on investment (ROI) was -59.3 percent. The company’s institutional ownership is monitored at 96.5 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 5 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.5. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Regional Management Corp. (NYSE:RM) is worth US$311.52 Million and has recently risen 0.49% to US$26.49. The latest exchange of 0.09 Million shares is below its average trading activity of 53.14 Million shares. The day began at US$26.04 but the price moved to US$25.51 at one point during the trading and finally capitulating to a session high of US$26.67. The stock tapped a 52-week high of US$37.21 while the mean 12-month price target for the shares is US$38.17.

Currently, the stock carries a price to earnings ratio of 9.87, a price to book ratio of 1.16, and a price to sales ratio of 1.06. For the past 5 years, the company’s revenue has grown 15%, while the company’s earnings per share has grown 2%. With an institutional ownership near 92%, it carries an earnings per share ratio of 2.69.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 4 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.